6%; the lower bound of the 95% CI for the mean rate of teratogenicity with efavirenz), the estimated number of excess teratogenic events was −5.65 events per 100 000 women (not shown in Fig. 1). Whether to use efavirenz in women of childbearing age learn more remains controversial. In the context of existing options for ART, limiting efavirenz use as a component of first-line therapy in HIV-infected women of childbearing age may lead to reductions in the increases in projected life expectancy produced by ART, but may also prevent teratogenic events. In this analysis, we found that projected survival for HIV-infected women receiving an efavirenz-based initial ART regimen was 0.89 years greater

than for women delaying efavirenz use and using an alternate first-line regimen (28.91 vs. 28.02 years, respectively), but efavirenz exposure was associated with a small (4.80

per 100 000 women) increased risk of teratogenic events. These life expectancy gains are larger than those associated with the use of both PCP and MAC prophylaxis (2.6 months or 0.22 years) [14]. The number of excess teratogenic events per 100 000 women ranged from 0.91 events in women aged 35–44 years to 11.73 events in women aged 15–24 years. The higher rate of excess teratogenic events in younger women is attributable to their increased rate of pregnancy (18.1 vs. 1.4 pregnancies per 100 person-years). Sensitivity analyses demonstrated that estimates of life expectancy and risk of excess teratogenic events are influenced by several important parameters. In the estimate of the risk of excess teratogenic events, Decitabine molecular weight the pregnancy rate and the teratogenicity risk with Dasatinib efavirenz exposure were the most influential parameters. Not surprisingly, the risk of excess teratogenic events attributable to efavirenz use was greater for women who are more likely to become pregnant. Data on pregnancy rates and outcomes in the modern ART era are limited. Because of the paucity of these data, we used pregnancy rates and outcomes reported in both the modern ART and pre-ART eras. Because more potent regimens have become available since these

data were reported, we varied the rates widely in sensitivity analysis to allow for changes in fertility and childbearing decisions made by HIV-infected women. In sensitivity analysis, the greatest impact on life expectancy occurred when the discount rate was increased from 0% (base case) to 5%. Changing the discount rate changes the relative attractiveness of treatment strategies that accrue benefits along different timelines. This is a way of giving more weight to events that occur immediately compared with those in the distant future. Changes in first-line ART viral suppression rates and CD4 benefits yielded less dramatic effects on life expectancy. However, sensitivity analysis does demonstrate variation in the efavirenz-related survival benefit. This analysis has several limitations.